Literature DB >> 2760486

Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis.

D K Henderson1, J L Gerberding.   

Abstract

Note from Dr. Merle A. Sande--Health care workers are at risk of acquiring human immunodeficiency virus (HIV) infection subsequent to accidental sticks with needles contaminated with blood from infected patients. The risk is small but real. Postexposure management is critically important, but few solid data are available. Can zidovudine (AZT, azidothymidine) prevent infection? How soon after exposure must the drug be given? At what dosage? For how long? Two leading authorities were asked to discuss this problem and to offer recommendations. Both have developed programs in their institutions, Dr. David K. Henderson at the Warren Grant Magnuson Clinical Center at the National Institutes of Health and Dr. Julie L. Gerberding at the University of California, San Francisco.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760486     DOI: 10.1093/infdis/160.2.321

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Zidovudine after occupational exposure to HIV.

Authors:  D J Jeffries
Journal:  BMJ       Date:  1991-06-08

2.  An ethics committee's recommendations on testing patients for HIV antibodies when health care workers suffer exposure to blood-borne pathogens.

Authors:  N S Wenger; J W Ross; R T Young
Journal:  HEC Forum       Date:  1991

3.  Zidovudine for prophylaxis of human immunodeficiency virus infection after accidental exposure.

Authors:  L S Binder; J A Chappell
Journal:  West J Med       Date:  1991-09

4.  Zidovudine after occupational exposure to HIV.

Authors:  D Elkharrat; J L Wautier; C Caulin; N Bonnet
Journal:  BMJ       Date:  1991-08-03

5.  Zidovudine prophylaxis following exposure to human immunodeficiency virus.

Authors:  R A Miller
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

Review 6.  Zidovudine (Retrovir) update.

Authors:  A R Rachlis
Journal:  CMAJ       Date:  1990-12-01       Impact factor: 8.262

Review 7.  Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.

Authors:  F Kamali
Journal:  Clin Investig       Date:  1993-05

8.  Simultaneous human immunodeficiency virus and Hepatitis C infection following a needlestick injury.

Authors:  J M Garcés; H Yazbeck; T Pi-Sunyer; J Gutiérrez-Cebollada; J L López-Colomés
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

9.  In vitro and in vivo studies on the prenatal toxicity of five virustatic nucleoside analogues in comparison to aciclovir.

Authors:  S Klug; C Lewandowski; H J Merker; R Stahlmann; L Wildi; D Neubert
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

10.  Cost effectiveness of human immunodeficiency virus postexposure prophylaxis for healthcare workers.

Authors:  D C Scheid; R M Hamm; K W Stevens
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.